Finance

Lists
Why is GLENMARK up 4.60%?
Dive Deeper
GLENMARK:NSE
Glenmark Pharmaceuticals Ltd
₹ 2,293.00
+4.60%
(+100.80) 1D
10-р сарын 9, 15:30:00 (GMT+5:30)  ·   INR
All symbols
SymbolPriceChange% Change
Generating top insights for GLENMARK...
Open
₹ 2,207.00
High
₹ 2,293.00
Low
₹ 2,203.00
Mkt. cap
647.14Т
Avg. vol.
588.18 мян
Volume
414.34 мян
Dividend
0.22%
Quarterly dividend
₹ 1.25
Ex-dividend date
2025 оны 10-р сарын 3
P/E ratio
36.01
52-wk high
₹ 2,537.60
52-wk low
₹ 1,792.60
EPS
₹ 63.68
Shares outstanding
0.00
No. of employees
17 мян
Open
₹ 2,207.00
High
₹ 2,293.00
Low
₹ 2,203.00
Mkt. cap
647.14Т
Avg. vol.
588.18 мян
Volume
414.34 мян
Dividend
0.22%
Quarterly dividend
₹ 1.25
Ex-dividend date
2025 оны 10-р сарын 3
P/E ratio
36.01
52-wk high
₹ 2,537.60
52-wk low
₹ 1,792.60
EPS
₹ 63.68
Shares outstanding
0.00
No. of employees
17 мян
News stories
From web sources and news partners
Profile
Glenmark Pharmaceuticals Limited is an Indian multinational pharmaceutical company based in Mumbai. Founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer, it is listed on the Bombay Stock Exchange and the National Stock Exchange of India. The company produces and distributes medicines in more than 80 countries, with operations concentrated in India, North America, Europe, and emerging markets. As of March 2026, it employed approximately 17,000 people. Its name derives from Saldanha's sons, Glenn and Mark. Wikipedia
About Glenmark Pharmaceuticals Ltd
CEO-
Employees16.9 мян
Founded1977 оны 11-р сарын 18
Headquarters-
SectorPharmaceutical industry
Last report
2026 оны 8-р сарын 3
Fiscal period
Q1 2027
₹ 17.11 / ₹ 17.30
-1.10%miss
Revenue / Est. (INR)
40.18 тэрбум / 39.17 тэрбум
+2.60%beat
Fiscal Q1 2027 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in INR
Loading Previous Earnings...
Revenue
Net income
All values in INR
2025 оны 9-р сар
2025 оны 12-р сар
2026 оны 3-р сар
2026 оны 6-р сар
Revenue
60.47 тэрбум
39.01 тэрбум
38.31 тэрбум
40.18 тэрбум
Cost of goods sold
12.65 тэрбум
12.95 тэрбум
13.65 тэрбум
12.46 тэрбум
Cost of revenue
12.65 тэрбум
12.95 тэрбум
13.65 тэрбум
12.46 тэрбум
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
10.86 тэрбум
8.41 тэрбум
16.49 тэрбум
9.35 тэрбум
Operating expense
25.64 тэрбум
18.90 тэрбум
17.91 тэрбум
21.41 тэрбум
Total operating expenses
38.29 тэрбум
31.85 тэрбум
31.56 тэрбум
33.87 тэрбум
Operating income
22.18 тэрбум
7.15 тэрбум
6.75 тэрбум
6.32 тэрбум
Other non operating income
2.01 тэрбум
444.65 сая
-2.72 тэрбум
657.64 сая
EBT including unusual items
9.67 тэрбум
5.34 тэрбум
3.88 тэрбум
6.43 тэрбум
EBT excluding unusual items
23.53 тэрбум
7.18 тэрбум
7.61 тэрбум
6.43 тэрбум
Income tax expense
3.57 тэрбум
1.31 тэрбум
864.49 сая
1.61 тэрбум
Effective tax rate
36.90%
24.49%
22.29%
24.96%
Other operating expenses
13.37 тэрбум
8.94 тэрбум
-55.65 сая
10.33 тэрбум
Net income
6.10 тэрбум
4.03 тэрбум
3.01 тэрбум
4.83 тэрбум
Net profit margin
10.09%
10.34%
7.87%
12.02%
Earnings per share
-
19.21
20.96
17.11
Interest and investment income
-
-
413.36 сая
-
Interest expense
-664.63 сая
-414.32 сая
-426.04 сая
-539.97 сая
Net interest expenses
-664.63 сая
-414.32 сая
-12.68 сая
-539.97 сая
Depreciation and amortization charges
1.41 тэрбум
1.54 тэрбум
1.48 тэрбум
1.73 тэрбум
EBITDA
23.54 тэрбум
7.80 тэрбум
7.80 тэрбум
7.75 тэрбум
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
Google аппс